These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Vedolizumab for the treatment of inflammatory bowel disease. Haddley K Drugs Today (Barc); 2014 Apr; 50(4):309-19. PubMed ID: 24918648 [TBL] [Abstract][Full Text] [Related]
28. A product review of vedolizumab in inflammatory bowel disease. Battat R; Dulai PS; Jairath V; Vande Casteele N Hum Vaccin Immunother; 2019; 15(10):2482-2490. PubMed ID: 30897022 [TBL] [Abstract][Full Text] [Related]
29. Responsiveness to Vedolizumab Therapy in Ulcerative Colitis is Associated With Alterations in Immune Cell-Cell Communications. Hsu P; Choi EJ; Patel SA; Wong WH; Olvera JG; Yao P; Liu YC; Tsai MS; Wang W; Boland BS; Chang JT Inflamm Bowel Dis; 2023 Oct; 29(10):1602-1612. PubMed ID: 37235748 [TBL] [Abstract][Full Text] [Related]
30. Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases. Saruta M; Papadakis KA Gastroenterol Clin North Am; 2014 Sep; 43(3):581-601. PubMed ID: 25110260 [TBL] [Abstract][Full Text] [Related]
31. Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells. Jovani M; Danese S Curr Drug Targets; 2013 Nov; 14(12):1433-43. PubMed ID: 23980911 [TBL] [Abstract][Full Text] [Related]
32. Anti-β7 integrin treatment impedes the recruitment on non-classical monocytes to the gut and delays macrophage-mediated intestinal wound healing. Sommer K; Heidbreder K; Kreiss L; Dedden M; Paap EM; Wiendl M; Becker E; Atreya R; Müller TM; Atreya I; Waldner M; Schürmann S; Friedrich O; Neurath MF; Zundler S Clin Transl Med; 2023 Apr; 13(4):e1233. PubMed ID: 37029786 [TBL] [Abstract][Full Text] [Related]
33. Circulating integrin alpha4/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype. Lord JD; Long SA; Shows DM; Thorpe J; Schwedhelm K; Chen J; Kita M; Buckner JH Clin Immunol; 2018 Aug; 193():24-32. PubMed ID: 29842945 [TBL] [Abstract][Full Text] [Related]
34. Novel Insights into the Mechanisms of Gut Homing and Antiadhesion Therapies in Inflammatory Bowel Diseases. Zundler S; Neurath MF Inflamm Bowel Dis; 2017 Apr; 23(4):617-627. PubMed ID: 28296823 [TBL] [Abstract][Full Text] [Related]
35. Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype. Milch C; Wyant T; Xu J; Parikh A; Kent W; Fox I; Berger J J Neuroimmunol; 2013 Nov; 264(1-2):123-6. PubMed ID: 24067534 [TBL] [Abstract][Full Text] [Related]
36. Vedolizumab-mediated integrin α4β7 blockade does not control HIV-1SF162 rebound after combination antiretroviral therapy interruption in humanized mice. Ling L; Wu T; To KKW; Cheung KW; Lui KOL; Niu M; Lam KS; Wang CC; Li J; Wang H; Yuen KY; Chen Z AIDS; 2019 Mar; 33(4):F1-F12. PubMed ID: 30829743 [TBL] [Abstract][Full Text] [Related]
37. Return to sender: Lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis. de Krijger M; Wildenberg ME; de Jonge WJ; Ponsioen CY J Hepatol; 2019 Sep; 71(3):603-615. PubMed ID: 31108158 [TBL] [Abstract][Full Text] [Related]
38. Vedolizumab for the Treatment of Noninflammatory Bowel Disease Related Enteropathy. Akhtar HJ; Nguyen TM; Ma C; Jairath V Clin Gastroenterol Hepatol; 2022 Mar; 20(3):e614-e623. PubMed ID: 33618025 [TBL] [Abstract][Full Text] [Related]